EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals
Open Access
- 2 June 2023
- journal article
- editorial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2341-2348
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Genomic Models of Short-Term Exposure Accurately Predict Long-Term Chemical Carcinogenicity and Identify Putative Mechanisms of ActionPLOS ONE, 2014
- Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humansFood and Chemical Toxicology, 2013
- Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: The dalcetrapib experienceToxicology and Applied Pharmacology, 2012
- Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995–2009)Regulatory Toxicology and Pharmacology, 2011
- An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity TestingToxicologic Pathology, 2011
- Background and Framework for ILSI's Collaborative Evaluation Program on Alternative Models for Carcinogenicity AssessmentToxicologic Pathology, 2001
- Mechanisms of Nongenotoxic Carcinogenesis and Assessment of the Human HazardRegulatory Toxicology and Pharmacology, 2000
- Carcinogenicity Testing and the Evaluation of Regulatory Requirements for PharmaceuticalsRegulatory Toxicology and Pharmacology, 1997
- The Utility of Two Rodent Species in Carcinogenic Risk Assessment of Pharmaceuticals in EuropeRegulatory Toxicology and Pharmacology, 1997
- The Redundancy of Mouse Carcinogenicity BioassaysToxicological Sciences, 1983